Please provide your email address to receive an email when new articles are posted on . Edward V. Loftus Jr. Though I see some interesting mirrors between pediatric and adult gastroenterology in the ...

Constipation in children can be caused by a range of problems including the use of certain medications, poor health or a lack of proper nutrition. A teenager who freezes when confronted with using the ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric ...

Credit: Getty Images. The application was supported by data from a phase 3 trial that included 330 patients 6 to 17 years of age with functional constipation. The Food and Drug Administration (FDA) ...

The FDA just approved a new medication called Linzess (linaclotide) for kids aged 7 and older who have irritable bowel syndrome with constipation (IBS-C). This is a big deal because until now, there ...

A newly approved option for pediatric patients with functional constipation significantly increased the frequency of bowel movements and improved other burdensome symptoms as well, according to a ...

I received a question from one of our twitter followers about her daughter who was recently found to be constipated. She wanted some information on treating constipation. Do you know how common ...

Rates of unnecessary abdominal X-rays decreased from 62% to 24% in children seen in the emergency department (ED) for constipation after implementation of a quality improvement intervention. The study ...

The phase 3 trial included patients 6 to 17 years of age who fulfilled modified Rome III Criteria for child/adolescent functional constipation. Treatment with linaclotide improved the frequency of ...

(RTTNews) - Ironwood Pharmaceuticals, Inc. (IRWD), Monday announced that the U.S. Food and Drug Administration has approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages ...